ALSO NOTED: FDA investigates 5 neurological cases; DeLape resigns as Isolagen CEO; Tessera raises $8.5M; and much more...

> The FDA is investigating the case of five teenagers who contracted a rare neurological disease after receiving the vaccine Menactra for bacterial meningitis. Investigators want to determine if the cases are coincidental or linked to the vaccine. Story [1]

> Chutes & Ladders: Frank DeLape resigned as CEO of Isolagen. Susan Ciallella was named interim CEO. Release [2]

> Seattle-based Tessera has raised $8.5 million in its second round of venture capital. Release [3]

> Endo and Penwest Pharmaceuticals have announced positive data for two Phase III trials of its painkiller, oxymorphone ER. Release [4]

> Forbes Medi-Tech has been cleared to start a Phase II trial of a cholesterol-lowering drug, FM-VP4. Release [5]

> GlycoFi announced a collaboration with Eli Lilly to develop antibodies and therapeutic proteins. Release [6]

> The Burnham Institute is collaborating in the NCI-funded Center of Cancer Nanotechnology Excellence. Release [7]

> San Diego-based Metabasis Therapeutics has raised $41.3 million in a private placement of stock. Release [8]

> Allergan and GSK have agreed to accelerate the commercialization of Botox in Japan and China. Release [9]

And Finally… Experts say that if a newly-constituted Supreme Court does allow states to outlaw abortion, the common ulcer drug Cytotec, which is also used to induce abortions, could become a widely used alternative. Article [10]